• Twenty-Four Years After the Launch of the EU Orphan Regulation: Analyzing Dutch Price Dynamics, Biosimilars, and Generics for Orphan Medicinal Products

    May 1, 2025, 00:00

  • IPECAD Modeling Workshop 2023 Cross-Comparison Challenge on Cost-Effectiveness Models in Alzheimer’s Disease

    Apr 1, 2025, 00:00

  • Exploring a Patient-Centered Methodology to Identify Suitable Proxy Conditions as a Source for Utility Data, Using Alopecia Areata as a Case Example

    Apr 1, 2025, 00:00

  • Role of Health Equity in Health Technology Assessment Processes: A Landscape Analysis of 13 Health Systems in Asia

    Apr 1, 2025, 00:00

  • Cost-Effectiveness of a Digitally Supported Care Management Program for Caregivers of People With Dementia

    Apr 1, 2025, 00:00

  • The Application of Time-Driven Activity-Based Costing in Oncology: A Systematic Review

    Apr 1, 2025, 00:00

  • The Health Economics of Alzheimer’s Disease and Related Dementias

    Apr 1, 2025, 00:00

  • A United Kingdom Value Set for the Weight-Specific Adolescent Instrument for Economic Evaluation

    Apr 1, 2025, 00:00

  • How Do Individuals Value Worse-Than-Dead EQ-5D-5L Health States in Composite Time Trade-Off Tasks? A Qualitative Study

    Apr 1, 2025, 00:00

  • A Value Set for EQ-5D-5L in the United Arab Emirates

    Apr 1, 2025, 00:00

  • How Do Bundled Payment Initiatives Account for Differences in Patient Risk Profiles? A Systematic Review

    Apr 1, 2025, 00:00

  • Indirect Costs of Alzheimer’s Disease: Unpaid Caregiver Burden and Patient Productivity Loss

    Apr 1, 2025, 00:00

  • New IPECAD Open-Source Model Framework for the Health Technology Assessment of Early Alzheimer’s Disease Treatment: Development and Use Cases

    Apr 1, 2025, 00:00

  • Using Outcome Information During Consultation Yields Better Shared Decision Making, Better Patient Experiences, and More Positive Expectations: A Comparative Effectiveness Study

    Apr 1, 2025, 00:00

  • A Comparison of the Performance of 6 Surrogacy Models, Including Weighted Linear Regression, Meta-Regression, and Bivariate Meta-Analysis

    Apr 1, 2025, 00:00

  • Reviewer Acknowledgment

    Apr 1, 2025, 00:00

  • Changes in Out-of-Pocket Drug Expenditures Among Medicare Beneficiaries With Dementia Under the Inflation Reduction Act: A Simulation Study

    Apr 1, 2025, 00:00

  • Table of Contents

    Apr 1, 2025, 00:00

  • Age and Gender Differences in the Relationship Between Chronic Pain and Dementia Among Older Australians

    Apr 1, 2025, 00:00

  • A New Approach for Assessing the Value of Informal Care in Alzheimer’s Disease

    Apr 1, 2025, 00:00

  • The Excess Direct Social Costs of Dementia-Related Neuropsychiatric Symptoms: A Regionwide Cohort Study Beyond Silos

    Apr 1, 2025, 00:00

  • Editorial Board

    Mar 26, 2025, 10:50

  • The Impact of Chronic Conditions on Productivity-Adjusted Life-Years in Both the Workplace and Household Settings in the General Adult Population in Finland

    Mar 1, 2025, 00:00

  • Maternal Mental Health Spillovers From Child Illness and Disability: A Dynamic Panel Analysis

    Mar 1, 2025, 00:00

  • Economic Considerations in Designs and Modifications of Multiarm, Multistage Adaptive and Adaptive Platform Randomized Controlled Trials: A Systematic Literature Review

    Mar 1, 2025, 00:00

  • Social Return on Investment Analysis: A Mixed Methods Approach to Assessing the Value of Adult Hospice Services

    Mar 1, 2025, 00:00

  • Prevalence of Immature Survival Data for Anticancer Drugs Presented to the National Institute for Health and Care Excellence Between 2018 and 2022

    Mar 1, 2025, 00:00

  • The Psychometric Properties of the EQ-HWB and EQ-HWB-S in Patients With Breast Cancer: A Comparative Analysis With EQ-5D-5L, FACT-8D, and SWEMWBS

    Mar 1, 2025, 00:00

  • The Estimation of Health State Utility Values for Psychological Distress in Australia: Implications for Future Economic Evaluations

    Mar 1, 2025, 00:00

  • Evaluating the Health and Economic Impacts of Return-to-Work Interventions: A Modeling Study

    Mar 1, 2025, 00:00

  • Estimating the Lifetime Costs and Benefits of the Incredible Years Teacher Classroom Management Intervention Using Data From 30 Months Follow-Up of the Supporting Teachers and childRen in Schools Trial

    Mar 1, 2025, 00:00

  • Estimating the Economic Impacts for Caregivers of Young People With Mental Health Problems in a Brazilian Cohort

    Mar 1, 2025, 00:00

  • The Feasibility of Personalized Endpoints in Assessing Treatment Outcomes for Rare Diseases: A Pilot Study of Goal Attainment Scaling in SCN2A-Associated Developmental Epileptic Encephalopathy

    Mar 1, 2025, 00:00

  • Cost-Utility Analysis of Antipsychotic Reduction and Discontinuation in Patients With Long-Term Schizophrenia and Psychosis in English Mental Health Trusts: The RADAR Study

    Mar 1, 2025, 00:00

  • Table of Contents

    Mar 1, 2025, 00:00

  • Does Regulatory and Reimbursement Parallel Processing Provide Swifter Funded Access to Medicines for Patients? Evaluation of Cancer Medicines Using the Australian Parallel Process

    Mar 1, 2025, 00:00

  • Patient-Informed Value Elements in Cost-Effectiveness Analyses of Major Depressive Disorder Treatment: A Literature Review and Synthesis

    Mar 1, 2025, 00:00

  • Advancing Mental Health Economics: Insights From the Themed Section

    Mar 1, 2025, 00:00

  • Developing an Australian Value Set for the Recovering Quality of Life-Utility Index Instrument Using Discrete Choice Experiment With Duration

    Mar 1, 2025, 00:00

  • A Systematic Literature Review of Important and Meaningful Differences in the EQ-5D Index and Visual Analog Scale Scores

    Mar 1, 2025, 00:00

  • Economic Evaluation of 9 Intersectoral Strategies to Improve Youth Mental Health and Alleviate Financial Burden in Colombia Using System Dynamics Modeling

    Mar 1, 2025, 00:00

  • Editorial Board

    Feb 26, 2025, 12:14

  • The Influence of Recall and Timing of Assessment on the Estimation of Quality-Adjusted Life-Years When Health Fluctuates Recurrently

    Feb 1, 2025, 00:00

  • Generative Artificial Intelligence for Health Technology Assessment: Opportunities, Challenges, and Policy Considerations: An ISPOR Working Group Report

    Feb 1, 2025, 00:00

  • Financial Impacts of Paying for Gene Therapy for Sickle Cell Disease Under Alternative Pricing and Financing Mechanisms

    Feb 1, 2025, 00:00

  • Potential Biases in Post-Stroke Health Utility Estimates by Modified Rankin Scale Scores

    Feb 1, 2025, 00:00

  • A Standardized Measurement and Valuation Scale of Genomic Utility for Policy Decisions: The GUV Scale

    Feb 1, 2025, 00:00

  • Modeling the Potential Health, Health Economic, and Health Inequality Impact of a Large-Scale Rollout of the Drink Less App in England

    Feb 1, 2025, 00:00

  • An Application of the Checklist for Health Economic Quality Evaluations in a Systematic Review Setting

    Feb 1, 2025, 00:00

  • Economic Evaluations of Interventions Addressing Inequalities in Cancer Care: A Systematic Review

    Feb 1, 2025, 00:00

  • Exploring Social Preferences for Health and Well-Being Across the Digital Divide: A Qualitative Investigation Based on Tasks Taken From an Online Discrete Choice Experiment

    Feb 1, 2025, 00:00

  • Prescription Medication Use and Expenditure for Atrial Fibrillation in the United States

    Feb 1, 2025, 00:00

  • Table of Contents

    Feb 1, 2025, 00:00

  • Reporting Uncertainty Around Health-State Values: A Standard Method and Worked Example

    Feb 1, 2025, 00:00

  • Author Reply

    Feb 1, 2025, 00:00

  • Slipping Away: Slippage in Hazard Ratios Over Datacuts and Its Impact on Immuno-oncology Combination Economic Evaluations

    Feb 1, 2025, 00:00

  • The Cost-Effectiveness of Frontline Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia: In Pursuit of Treatment-Free Remission and Dose Reduction

    Feb 1, 2025, 00:00

  • A Systematic Review and Quality Assessment of Cardiovascular Disease–Specific Health-Related Quality-of-Life Instruments: Part II Psychometric Properties

    Feb 1, 2025, 00:00

  • Value Framework Based on Multiple-Criteria Decision Analysis for Assessment of New Health Technologies Under Universal Healthcare Coverage System in Taiwan

    Feb 1, 2025, 00:00

  • Healthcare Costs in the United States by Demographic Characteristics and Comorbidity Status

    Feb 1, 2025, 00:00

  • Measurement Equivalence of Standard and Zoom-Enabled Electronic Clinical Outcome Assessments: Implications for Patient Accessibility in Clinical Trials

    Feb 1, 2025, 00:00

  • Editorial Board

    Jan 31, 2025, 10:40

  • Editorial Board

    Jan 8, 2025, 14:39

  • Value Attribution for Combination Treatments: Two Potential Solutions for an Insoluble Problem

    Jan 1, 2025, 00:00

  • Primer on Health Equity Research in Health Economics and Outcomes Research: An ISPOR Special Interest Group Report

    Jan 1, 2025, 00:00

  • Most Common Symptomatic Adverse Reactions of Cancer Treatments From US Drug Labels (2015-2021) to Inform Selection of Patient-Reported Outcomes

    Jan 1, 2025, 00:00

  • Good Practices for Health Technology Assessment Guideline Development: A Report of the Health Technology Assessment International, HTAsiaLink, and ISPOR Special Task Force

    Jan 1, 2025, 00:00

  • Dysmenorrhea-Related Impact on Functioning Scale: Development and Measurement Properties for Cisgender Women and Transgender Men

    Jan 1, 2025, 00:00

  • Exploring Heterogeneity in the Cost-Effectiveness of High-Flow Nasal Cannula Therapy in Acutely Ill Children—Insights From the Step-Up First-line Support for Assistance in Breathing in Children Trial Using a Machine Learning Method

    Jan 1, 2025, 00:00

  • An Attribution of Value Framework for Combination Treatments

    Jan 1, 2025, 00:00

  • Will the Institute for Clinical and Economic Review’s Shared Savings Approach Decrease Value-Based Prices Most for the Most Severe Diseases?

    Jan 1, 2025, 00:00

  • Deriving a Preference-Weighted Measure for People With Hypoglycemia From the Hypo-RESOLVE QoL

    Jan 1, 2025, 00:00

  • Unpaid Caring and Health-Related Quality of Life: Longitudinal Analysis of Understanding Society (the UK Household Longitudinal Survey)

    Jan 1, 2025, 00:00

  • Challenges in Value Assessment for One-Time Gene Therapies for Inherited Retinal Diseases: Are We Turning a Blind Eye?

    Jan 1, 2025, 00:00

  • Cancer Drug Wastage and Mitigation Methods: A Systematic Review

    Jan 1, 2025, 00:00

  • Analytical Methods for Comparing Uncontrolled Trials With External Controls From Real-World Data: A Systematic Literature Review and Comparison With European Regulatory and Health Technology Assessment Practice

    Jan 1, 2025, 00:00

  • Economic Evaluation of Fasting Mimicking Diet Versus Standard Care in Diabetic Patients on Dual or Triple Medications at Baseline in the United States: A Cost-Utility Analysis

    Jan 1, 2025, 00:00

  • Development of a Health-State Classification System for the Pediatric Quality-of-Life Inventory Version 4.0 Generic Core Scales for Preference-Based Valuation in Australia

    Jan 1, 2025, 00:00

  • Proposal for a General Outcome-Based Value Attribution Framework for Combination Therapies

    Jan 1, 2025, 00:00

  • Virtual/Mobile Overdose Response in Canada: A Social Return on Investment Analysis

    Jan 1, 2025, 00:00

  • Table of Contents

    Jan 1, 2025, 00:00

  • A Review and Comparative Case Study Analysis of Real-World Evidence in European Regulatory and Health Technology Assessment Decision Making for Oncology Medicines

    Jan 1, 2025, 00:00

  • Editorial Board

    Dec 3, 2024, 18:32

  • CO125 The Impact of Insulin Dosage on Cancer Risk in Type 1 Diabetes: A Population-Based Study

    Dec 1, 2024, 00:00

  • HSD47 The Role and Importance of Evidence in US Payer Assessment and Formulary Decisions

    Dec 1, 2024, 00:00

  • HPR120 Is the Speed of Biosimilar Penetration Related to Demand-Side Polices?

    Dec 1, 2024, 00:00

  • CO24 Modeling Cardiovascular Event Reduction and Cost Savings With a CV Polypill (ASA + Atorvastatin + Ramipril) Versus Individual Components Post-Myocardial Infarction in Spain

    Dec 1, 2024, 00:00

  • CO43 Comparison of Novel Multilevel-Network Meta-Regression With Other Conventional Indirect Treatment Comparisons

    Dec 1, 2024, 00:00

  • EE341 Comparison of Markov Model and Dynamic Model in Economic Evaluations for Infectious Diseases: A Case of Bictegravir/Emtricitabine/Tenofovir Treatment-Native Adults of HIV-1 in China

    Dec 1, 2024, 00:00

  • HPR7 The Discrepancy in Real-World Evidence of New Drug Expenditure Between Actual and Estimated Figures From Manufacturers and Government Agencies in Taiwan

    Dec 1, 2024, 00:00

  • EE698 Real-World Impact of Immunotherapy on Survival and Hospital Costs in Advanced/Metastatic Lung Cancer: A Retrospective Analysis From the French Health Data System

    Dec 1, 2024, 00:00

  • EE654 Economic Modelling Approaches for Evaluating Interventions That Reduce Surgery Waiting Times

    Dec 1, 2024, 00:00

  • HTA107 Pilot Study of Digital Health Technologies for Managing Low Back Pain: Digital Therapeutics Value Assessment in South Korea

    Dec 1, 2024, 00:00

  • EE316 An Iterative Survey of Phenylketonuria (PKU) Medical Experts to Inform Health Economic Modeling Methods

    Dec 1, 2024, 00:00

  • P5 Air Pollution Control and Health Economic Burdens: Evidence From a Megacity in China From 2014 to 2022

    Dec 1, 2024, 00:00

  • EE323 Hospitalization Burden of Crohn's Disease and Ulcerative Colitis in the Middle Atlantic: A Six-Cohort Analysis of Pooled National In-Patient Data (2016-2020)

    Dec 1, 2024, 00:00

  • EE580 Cost-Utility of Acromegaly Second Line Pharmacological Treatments in Adult Patients in France

    Dec 1, 2024, 00:00

  • HPR204 Early Access Programmes in Europe Versus Key Markets in Other Regions: An In-Depth Comparison

    Dec 1, 2024, 00:00

  • EE674 Cost-Effectiveness of Pemigatinib for Patients With Advanced Intrahepatic Cholangiocarcinoma and FGFR2 Fusions/Rearrangements: 2024 FIGHT-202 Trial Final Results

    Dec 1, 2024, 00:00

  • EE535 Cost-Utility Analysis of an Advanced Hybrid Closed-Loop System vs Multiple Daily Injection Therapy With Intermittently Scanned Continuous Glucose Monitoring in People With Type 1 Diabetes and Above-Target HBA1C in France

    Dec 1, 2024, 00:00

  • EPH96 The Impact of Influenza in Older Age Groups in Portugal, 2015-2018

    Dec 1, 2024, 00:00

  • HPR113 Social Determinants of Health and Use of Glucagon-like Peptide-1 Receptor Agonists in the Pediatric Population

    Dec 1, 2024, 00:00

  • HTA168 Level of ICER of Health Economic Assessment in France in 2023

    Dec 1, 2024, 00:00

  • HSD112 Transforming Healthcare Access: Empowering Chinese Patients Through Generative AI Across City Tiers and Age Groups

    Dec 1, 2024, 00:00

  • HSD27 Implementing Outcome Measurement for Lung Cancer Patients at an Oncology Center

    Dec 1, 2024, 00:00

  • HTA53 Trends Underlying Positive and Negative Decision-Making for New Oncology Treatments Appraised by the National Institute for Health and Care Excellence (NICE) in 2023

    Dec 1, 2024, 00:00

  • P46 Comparing Data Collection Methods: Health Care Professional Survey-Based Chart Audit Versus Automated Electronic Health Record Databases in Multicountry Drug Utilization Studies

    Dec 1, 2024, 00:00

  • EPH279 Trends in Epidemiology and Mortality of Patients With Pancreatic Cancer in Germany: A Retrospective Study Using German Claims Data

    Dec 1, 2024, 00:00

  • HPR234 Access to Orphan Medicines in Portugal

    Dec 1, 2024, 00:00

  • Rare Diseases: Economic Evaluation and Policy Considerations [Editor's Choice]

    Dec 1, 2024, 00:00

  • EE245 Economic Burden in Patients With Chronic Myeloid Leukemia in Early Lines of Therapy: A Literature Review

    Dec 1, 2024, 00:00

  • EPH62 Effects of Shift Work on Food Choice Habits and Stress Levels of Nurses and Paramedics: A Cross-Sectional Study

    Dec 1, 2024, 00:00

  • EE419 Systematic Literature Review of Cost-Effectiveness Evaluations of Freestyle Libre Continuous Glucose Monitoring Systems

    Dec 1, 2024, 00:00

  • EE752 Avoided Costs Attributable to the Effectiveness of Optimal Management of Lipid-Lowering Agents in a Cohort of Patients at Cardiovascular Risk in the Colombian Caribbean

    Dec 1, 2024, 00:00

  • HSD49 Neoadjuvant Immunotherapy in Patients With Early-Stage, High-Risk, ER+/HER2– Breast Cancer: Physician Practices, Therapy Choice, and Barriers Among US Oncologists

    Dec 1, 2024, 00:00

  • EE725 Cost-Effectiveness of Linzagolix for Uterine Fibroids in Australia: A Healthcare Payer and Societal Perspective

    Dec 1, 2024, 00:00

  • EE376 Rheumatoid Arthritis, Cost-Effectiveness Analysis of Biosimilar Tocilizumab in Spain

    Dec 1, 2024, 00:00

  • P47 Evaluation of Natural Language Processing (NLP) on Electronic Medical Records: A Proof of Concept on Chronic Graft Versus Host Disease (cGVHD) in France

    Dec 1, 2024, 00:00

  • EE709 Cost-Effectiveness Analysis of Paxlovid® (Nirmatrelvir+Ritonavir) in Adults at High-Risk of Progression to Severe COVID-19 Disease in Portugal

    Dec 1, 2024, 00:00

  • EPH60 Temporal Trends in Vaccination and Antibiotic Use Among Young Children in the United States, 2000-2019

    Dec 1, 2024, 00:00

  • EE805 The Hazards of Applying Hazard Ratios to Accelerated Failure Time Models: A Simulation Study

    Dec 1, 2024, 00:00

  • HPR122 Innovative Approaches to Broaden Access in Chronic-High Prevalent Diseases (Obesity)

    Dec 1, 2024, 00:00

  • HPR97 More Public Funding? A Choice Experiment on the Healthcare Funding System for Older Populations

    Dec 1, 2024, 00:00

  • HPR205 An International Mapping Review of Medicines Approvals and Access to Innovative Technologies for the United Kingdom (UK): A Retrospective Analysis

    Dec 1, 2024, 00:00

  • EPH133 AI Using Real-Life Data, an Additional Diagnostic Tool for Doctors to Identify Patient at Very High Risk of Renal Failure

    Dec 1, 2024, 00:00

  • EE418 Cost-Utility Analysis of Flash Glucose Monitoring Systems in People With Type 2 Diabetes Mellitus and Poor Glycemic Control on Basal Insulin From the Spanish Health System Perspective

    Dec 1, 2024, 00:00

  • P43 Health-Related Quality of Life in People Living With Dementia: Over and Underestimation of Proxy-Ratings

    Dec 1, 2024, 00:00

  • HPR245 Baseline Characteristics of Patients Approved for Reimbursement of Liraglutide (Saxenda®) for Weight Management Under a Managed Access Protocol in Ireland

    Dec 1, 2024, 00:00

  • HTA188 Evaluating the Impact of Benefit Reassessment Outcomes for Orphan Drugs Surpassing the Revenue Limit in Germany

    Dec 1, 2024, 00:00

  • CO28 Analysis of Prophylactic Treatment of Patients With Hereditary Angioedema in the Slovak Republic in 2022: Results of the Descriptive Cross-Sectional Database Study

    Dec 1, 2024, 00:00

  • EE401 Budgetary Impact of Pre-Therapeutic DPD Deficiency Screening in Fluoropyrimidine-Treated Cancer Patients in Algeria

    Dec 1, 2024, 00:00

  • HPR68 How to Overcome the Remaining Challenges for Successful Implementation of the EU HTA Regulation: Key Insights From the 2023 European Access Academy Spring Convention and Survey

    Dec 1, 2024, 00:00

  • EE699 The Benefit of Introducing Remimazolam for Procedural Sedation in Belgian Clinical Practice

    Dec 1, 2024, 00:00

  • HTA84 Validation of the AI-Based Early Reimbursement Planning Search Engine in Main European Countries and the USA

    Dec 1, 2024, 00:00

  • EE702 A QALY is a QALY is a QALY: Nope

    Dec 1, 2024, 00:00

  • CO38 Burden and Trends of COPD Exacerbations in France Before and During the Pandemic

    Dec 1, 2024, 00:00

  • EPH260 Cost of Treatment for Mucopolysaccharidosis IV-A in a Poor Population in Colombia

    Dec 1, 2024, 00:00

  • HTA197 Recent Trends From UKs Cancer Drugs Fund, Key Drivers of Acceptance

    Dec 1, 2024, 00:00

  • EPH163 Economic Burden Associated With Post-Partum Hemorrhage: A Targeted Literature Review

    Dec 1, 2024, 00:00

  • The Impact of Additive Population(s), Intervention, Comparator(s), and Outcomes in a European Joint Clinical Health Technology Assessment

    Dec 1, 2024, 00:00

  • EE458 Evaluating Utilization Patterns, Financial Impact, and Access Delay Caused by Reimbursement Criteria on Public Drug Plans for Primary Care Topical Treatments in Canada: Case Study With HP/TAZ Combination for Plaque Psoriasis

    Dec 1, 2024, 00:00

  • HSD94 Economic Impacts of Artificial Intelligence (AI)-Based Risk Analytics for Early Detection of Clinical Deterioration in a Pragmatic Randomized Controlled Trial: Need for Innovative Approaches to Understand Costs for AI Systems

    Dec 1, 2024, 00:00

  • HPR133 The Global Impact of EU HTA: Insights From 13 Non-EU Countries

    Dec 1, 2024, 00:00

  • CO83 Utilization and Outcomes of Extracorporeal Membrane Oxygenation in China and Scandinavia: A Systemic Literature Review

    Dec 1, 2024, 00:00

  • EE647 Budget Impact Analysis of Fixed-Duration Ibrutinib+Venetoclax As Frontline Treatment of Chronic Lymphocytic Leukemia in the Brazilian Private Healthcare System

    Dec 1, 2024, 00:00

  • CO64 Systematic Review of Methimazole in Graves' Disease Management: Treatment Variations and Efficacy Outcomes

    Dec 1, 2024, 00:00

  • CO13 Impact on Health Outcomes and Productive Work of Anti-PD-(L)1 Inhibitors to Treat Early-Stage Cancers in England

    Dec 1, 2024, 00:00

  • EE476 Cost-Minimization and Budget Impact Analysis of Abiraterone (Tarosyn® and Avitosyn®) as Second Line Treatment for Metastatic Prostate Cancer Resistant to Castration in Mexico

    Dec 1, 2024, 00:00

  • EE503 Key Features of Economic Models Used in Submissions to NICE in Dermatology Indications

    Dec 1, 2024, 00:00

  • EE733 Budget Impact Analysis of Metreleptin in Patients With Lipodystrophy in Saudi Arabia

    Dec 1, 2024, 00:00

  • HTA72 Evolving National Health Technology Assessment (HTA) Frameworks in Theory Versus Practice in the Asia-Pacific (APAC) Region: A Targeted Literature HTA Review Focusing on Australia, Japan, and Taiwan

    Dec 1, 2024, 00:00

  • HSD2 Optimizing Radiotherapy Utilization Through Systematic and Synergistic Real-Time Monitoring

    Dec 1, 2024, 00:00

  • HPR248 Willingness to Pay for Ultra-Rare Diseases in US, Germany, France, UK, and Japan: A Comparative Study

    Dec 1, 2024, 00:00

  • EPH80 Impact of the COVID-19 Pandemic on Arterial Hypertension Monitoring and Control in Portugal

    Dec 1, 2024, 00:00

  • EPH102 Healthcare Utilization Among RTT Patients With Aspiration and Epilepsy in a Center of Excellence Medical Center in the United States

    Dec 1, 2024, 00:00

  • EE540 Cost-Effectiveness of Next Generation Sequencing to Select Microsatellite Stable/Mismatch Repair Proficient Metastatic Colorectal Cancer Patients for Immune Checkpoint Inhibitor Therapy

    Dec 1, 2024, 00:00

  • CO81 Pregabalin Utilization and Side Effects Among Hemodialysis Patients Diagnosed With Pruritus or Neuropathic Pain in US Claims Data

    Dec 1, 2024, 00:00

  • EPH205 Overall Survival in Individuals Diagnosed With Progressive Multifocal Leukoencephalopathy

    Dec 1, 2024, 00:00

  • CO134 The Impact of Approved Anti-Obesity Medications on the Incidence of Obstructive Sleep Apnea, Healthcare Resource Utilization and Costs Among Patients, with Obesity: A Retrospective Cohort Study

    Dec 1, 2024, 00:00

  • EE617 An Italian Pharmacoutilization Analysis in Patients With Hemophilia A With and Without Inhibitors After Switching to Emicizumab

    Dec 1, 2024, 00:00

  • EE339 Cost and Healthcare Resource Utilization (HRU) Among Patients Living with Angelman Syndrome (AS): A Systematic Review

    Dec 1, 2024, 00:00

  • EPH252 Estimating the Size of the Brazilian Population in Supplementary Healthcare System in Secondary Prevention of Cardiovascular Disease: An Analysis of the Potential for Lipid-Lowering Treatment Beyond Statin and Ezetimibe

    Dec 1, 2024, 00:00

  • EE345 Development of the Piccoteam Reference Case for Economic Evaluation of Precision Medicine

    Dec 1, 2024, 00:00

  • HPR74 Enhancing the Acceptance of Externally Controlled Trials (ECTs) in the German HTA System: Analysis of Guidance Documents From Other Countries

    Dec 1, 2024, 00:00

  • EE739 Estimated Incremental Direct All-Cause Healthcare Costs Associated With Multimorbidity Amongst Patients With Sickle Cell Disease (SCD) in England

    Dec 1, 2024, 00:00

  • EPH84 Burden of Hospital Candidemia in Fran Diagnostic Performance of an Administrative Hospital Database for Case Identification in a French University Hospital

    Dec 1, 2024, 00:00

  • EE623 Budget Impact Analysis of Empagliflozin for Adults With Chronic Kidney Disease (CKD) in Greece

    Dec 1, 2024, 00:00

  • CO25 PRO-WAVE1: Monitoring Patient Reported Outcomes (PROs) in Prostate Cancer Through Wave Health: A Novel ePRO Health Platform

    Dec 1, 2024, 00:00

  • EPH243 First Real-World Evidence Onbudesonide/Glycopyrronium/Formoterol Fumarate(BGF) Use for COPD Patients in France (ENARXI Study)

    Dec 1, 2024, 00:00

  • EE257 Modeling the Potential Public Health Impact and Cost-Effectiveness of BNT162B2 COVID-19 Booster Vaccination in Mexico

    Dec 1, 2024, 00:00

  • EE504 Leveraging Large Language Models for Conceptualizing Health Economic Models: A Feasibility Study in Oncology

    Dec 1, 2024, 00:00

  • EE492 Cost-Effectiveness of CDK4/6 Inhibitors (CDK4/6i) in First- vs Second-Line for Advanced Breast Cancer in the Phase 3 SONIA Trial (BOOG 2017-03)

    Dec 1, 2024, 00:00

  • HTA109 European Joint Clinical Assessment: How Many PICOs Are Too Many?

    Dec 1, 2024, 00:00

  • EPH32 Trends in Benzodiazepine and Z-Drug Prescribing and Long-Term Use in Hong Kong: A Descriptive Cross-Sectional Study

    Dec 1, 2024, 00:00

  • EE281 Cost-Effectiveness Analysis of Bimekizumab in Patients With Axial Spondyloarthritis (AXSPA) in Greece

    Dec 1, 2024, 00:00

  • EE582 Approaches to Discussions on Confidential Pricing Whilst Enabling Analysis of “True” Budget Impact

    Dec 1, 2024, 00:00

  • EE314 A Cost-Utility Analysis in Patients With Inflammatory Bowel Disease and Iron Deficiency Anemia in the Netherlands: Reduced Hypophosphatemia and Fracture Incidence With Ferric Derisomaltose Versus Ferric Carboxymaltose

    Dec 1, 2024, 00:00

  • CO37 Glucagon-like Peptide-1 Receptor Agonists for Adult Obesity: Where Next?

    Dec 1, 2024, 00:00

  • EE714 Identifying Patients With High Economic Burden Using Real-World Data: The Case of Myasthenia Gravis (MG)

    Dec 1, 2024, 00:00

  • EE614 Are Different Generations of Ceramic-on-Ceramic Implants More Cost-Effective Than Metal-on-Polyethylene Implants in Primary Total Hip Arthroplasty?

    Dec 1, 2024, 00:00

  • HTA162 Development of an NCPE-Adjusted Base Case: Assessment and Adjustment of Applicant Base Cases From the Perspective of a Health Technology Assessment Body

    Dec 1, 2024, 00:00

  • HSD138 Future Development Direction Obtained Through an Analysis of the Status and Effectiveness of Care Robots by Type: A Systematic Review

    Dec 1, 2024, 00:00

  • HSD122 Burden of Low Molecular Weight Heparin Switching in the UK and Canada

    Dec 1, 2024, 00:00

  • EPH197 Risk of Drug-Induced Interstitial Lung Disease in Korean Patients With Lung Cancer: A Nested Case-Control Study

    Dec 1, 2024, 00:00

  • EE483 The Contribution of Innovative Drugs and the National Reimbursement Drug List to Human and Physical Capital in the Social Economy: A Case of Blood Cancer in China

    Dec 1, 2024, 00:00

  • EE804 Cost-Effectiveness of Dupilumab in the Treatment of Moderate-to-Severe Prurigo Nodularis in France

    Dec 1, 2024, 00:00

  • HSD72 Real World Evidence on Impact of Clinical Decision Support System (CDSS) Alerts on General Practitioners Adherence to the New Gastro-Oesophageal Reflux Disease Treatment Guidelines in German Primary Care Settings

    Dec 1, 2024, 00:00

  • EPH288 Characteristics of NASH Patients Who Develop Hepatocellular Carcinoma (HCC) With and Without a Corresponding Cirrhosis Diagnosis

    Dec 1, 2024, 00:00

  • EPH255 Understanding Alopecia Areata: An Estimation of the Portuguese Epidemiology Data

    Dec 1, 2024, 00:00

  • HTA204 Treatment Waning in Dutch Pharmaceutical Submissions: An Exploratory Study

    Dec 1, 2024, 00:00

  • HSD45 The Dental Care Needs and the Government's Intervention Service in People With Special Needs in Taiwan

    Dec 1, 2024, 00:00

  • EE598 The Economic Burden of HER2+ Breast Cancer and the Targeted Therapies Epidemiological Economic Impact in the Anita Moreno Hospital of Panama

    Dec 1, 2024, 00:00

  • EE620 Cost-Effectiveness of PCV15 in the Pediatric Population for Preventing Pneumococcal Disease in France

    Dec 1, 2024, 00:00

  • HPR161 Variation of Cost-Effectiveness Across the Population, Treatment Cost and Adoption Decision: A Case Study in CVD Prevention

    Dec 1, 2024, 00:00

  • HPR138 Analysis of Health Technology Assessments of Lung Cancer Therapies in Germany in the Last Decade: Is There an Association Between Added Benefit Ratings and Negotiated Reimbursement Prices?

    Dec 1, 2024, 00:00

  • EPH179 Real-Time Identification of Infectious Disease Symptoms Through AI-Powered Text Mining From Anonymized Electronic Health Records

    Dec 1, 2024, 00:00

  • HTA132 One for All? Exploring the Need for Country Specific Value Sets for Preference-Based Measures of Health

    Dec 1, 2024, 00:00

  • HTA124 Payer Perceptions of Supportive Evidence in the Estimation of Long-Term Durability for Gene Therapies in Major European Markets

    Dec 1, 2024, 00:00

  • HSD127 Real-World Patterns of Tyrosine Kinase Inhibitor (TKI) Discontinuation and Reinitiation in Chronic Myeloid Leukemia (CML) Patients in the United States

    Dec 1, 2024, 00:00

  • HPR249 Utilization and Expenditure on Sacubitril/Valsartan (Entresto®) Over a Five-Year Period Under a Reimbursement Application System in Ireland

    Dec 1, 2024, 00:00

  • EE544 Early Cost-Effectiveness Analysis of AI-Enhanced Remote Monitoring Solutions for Timely Detection of Advanced Parkinson's Disease in Finland

    Dec 1, 2024, 00:00

  • EPH171 Factors Associated with Fracture Recurrence in Patients With Osteoporotic Fractures: A Population-Based Study in South Korea

    Dec 1, 2024, 00:00

  • EE365 Economic Evaluation of Transcatheter Aortic Valve Implantation (TAVI) Relative to Other Interventions in Cardiovascular and Oncology Disease Areas: A Targeted Literature Review

    Dec 1, 2024, 00:00

  • EE641 Multi-Perspective Analysis of Hospital Costs in Fran Case Study on the French System

    Dec 1, 2024, 00:00

  • EE817 Exploring the Impact of the New NICE Disease Severity Modifier on HTA Oncology Submissions: A Retrospective Analysis of Technology Appraisals

    Dec 1, 2024, 00:00

  • EE404 Cost-Effectiveness of Rapid Direct Multiplex PCR Test for Diagnosing Meningitis and Encephalitis From the Brazilian Public Perspective

    Dec 1, 2024, 00:00

  • HTA138 NICE vs SMC: Reimbursement Differences for Non-Oncology Orphan Drugs

    Dec 1, 2024, 00:00

  • HPR253 Drug Development and Launch Timeline Analysis Across 6 High-Income Countries: From Pivotal Trial to HTA

    Dec 1, 2024, 00:00

  • EE613 Cost-Effectiveness Analysis of RSVPreF3 OA Vaccine in Sweden for Adults Aged ≥ 60 Years

    Dec 1, 2024, 00:00

  • EPH256 Separating Fact From Fiction: Potential Use of Post-Authorization Safety Studies to Assess Safety of GLP-1s in Obesity Treatment

    Dec 1, 2024, 00:00

  • CO30 Real-World Treatment Patterns in Patients With Biochemical Recurrence After Local Therapy for Prostate Cancer: Retrospective Analysis of a Large US Database

    Dec 1, 2024, 00:00

  • HPR135 Current Barriers and Strategies for Optimizing Access to Onco-Hematological Drug Combinations in Spain: Multidisciplinary Delphi Consensus

    Dec 1, 2024, 00:00

  • EE307 Comparing Ancillary Services Associated With Subcutaneous Versus Intravenous Medication Administration

    Dec 1, 2024, 00:00

  • CO65 Indirect Treatment Comparison of Biologic Treatments in Adolescents With Moderate to Severe Atopic Dermatitis: A Systematic Literature Review and Network Meta Analysis

    Dec 1, 2024, 00:00

  • HPR154 Comparison of Generic Drug Prices Between China and the United States

    Dec 1, 2024, 00:00

  • EPH190 Real-World Treatment of Newly Diagnosed Patients With Acute Myeloid Leukemia and Aged Between 60 and 75 Years: Analysis of Key Drivers for Chemotherapy Selection in France and Germany

    Dec 1, 2024, 00:00

  • EE554 Global Dynamics of Drug Pricing: Analyzing the Influence of Emerging Countries on Pricing Strategies in Developed Nations

    Dec 1, 2024, 00:00

  • Toward Patient-Centered Drug Approval for Treatment of Rare Diseases

    Dec 1, 2024, 00:00

  • HPR146 Did the EMA and FDA Accelerated Approval Pathways Reverse the Drought in Novel Anti-Infectives?

    Dec 1, 2024, 00:00

  • EE530 Cost-Effectiveness of Orphan Medicines for the Management of Spinal Muscular Atrophy: Thinking Outside the Box

    Dec 1, 2024, 00:00

  • EE377 Cost-Effectiveness of Nirmatrelvir/Ritonavir in COVID-19 Patients at High-Risk for Progression in Spain

    Dec 1, 2024, 00:00

  • EE693 Cost-Effectiveness of Atidarsagene Autotemcel (ARSA-CEL) Gene Therapy for Treating Metachromatic Leukodystrophy (MLD) in Ireland, Belgium, and the Netherlands As a Part of the Beneluxa Initiative

    Dec 1, 2024, 00:00

  • CO16 Savings Associated With the Optimization of Pharmacological Therapy in Patients With Chronic Respiratory Pathologies

    Dec 1, 2024, 00:00

  • EE794 Assessing the Impact of Introducing Mavacamten for the Treatment of Obstructive HCM on the Modelled System and Societal Level Burden in China

    Dec 1, 2024, 00:00

  • EE484 Evaluating the Cost-Effectiveness of Dabrafenib and Trametinib for the Treatment of Pediatric Patients With Relapsed or Refractory High-Grade Glioma in England and Wales

    Dec 1, 2024, 00:00

  • HTA51 Health Equity and HTA: The HTA Agencies Are Asking for Equity Data, But Are They Using It?

    Dec 1, 2024, 00:00

  • EPH19 Ovarian Cancer Age-Adjusted Mortality Rates in Chile During 2002-2019

    Dec 1, 2024, 00:00

  • HTA190 Using Real-World Evidence in Health Technology Assessment Submissions: A NICE Case Study

    Dec 1, 2024, 00:00

  • CO131 Comparative Efficacy of Elafibranor and Seladelpar in Patients With Primary Biliary Cholangitis: A Network Meta-Analysis

    Dec 1, 2024, 00:00

  • CO115 LDL-C Goals Attainment in Patients at Very High Cardiovascular Risk: A Multicentric RWE Evaluation in Colombia

    Dec 1, 2024, 00:00

  • EE277 Cost of Stroke in Latin America: A Multicentric Time-Driven Activity-Based Costing Study

    Dec 1, 2024, 00:00

  • EE682 Carbetocin for the Prevention of Postpartum Hemorrhage Due to Uterine Atony Following Vaginal Delivery: A Retrospective Cost-Benefit Analysis Based on Clinical Experience from Polish Medical Centers

    Dec 1, 2024, 00:00

  • HPR27 Guideline for Health Economic Evaluation of Medicines: A Proposal by the Advisory Committee for Financing Pharmaceutical Benefits (CAPF) in the Spanish National Health System

    Dec 1, 2024, 00:00

  • HTA195 Assessment of Time to HTA Outcome for Novel Oncology Combinations and Decision Drivers Across UK and Europe

    Dec 1, 2024, 00:00

  • EE407 Budget Impact Analysis of Paliperidone Palmitate in Chronic Schizophrenia in the Mental Health Secretariat-Egyptian Ministry of Health

    Dec 1, 2024, 00:00

  • EE720 Cost-Effectiveness of Faricimab in Canada for the Treatment of Patients With Macular Edema Secondary to Retinal Vein Occlusion

    Dec 1, 2024, 00:00

  • EE498 Cost-Effectiveness of a Photopethysmographic Test for Screening for Atrial Fibrillation in Three European Countries Including Indirect Costs

    Dec 1, 2024, 00:00

  • EPH217 Prescription Medication Patterns and Polypharmacy Among Chinese Patients With Diabetes: A Retrospective Cohort Study

    Dec 1, 2024, 00:00

  • HTA111 EU Joint Clinical Assessment (JCA): Uncertain Impact on German Amnog Timelines and Potential Delays

    Dec 1, 2024, 00:00

  • EE685 What Is the Real Price of Switching Medical Technologies? Evaluation of Financial and Value-Based Aspects: The Case for Dialysis

    Dec 1, 2024, 00:00

  • EE820 Cost-Utility Analysis of an All-Preterm Infant Immunization With Nirsevimab Against Respiratory Syncytial Virus (RSV): Associated Disease at the Brazilian Private Healthcare System

    Dec 1, 2024, 00:00

  • HPR187 Injectable Oncology Therapies: Benchmarking Gross and Net Price Differentials in Europe vs US

    Dec 1, 2024, 00:00

  • HPR166 Understanding Differences in Pharmaceutical Products Based on Price Publication Status

    Dec 1, 2024, 00:00

  • EE610 Age-Targeted Vaccination for Reducing Clostridioides Difficile Infection in England: A Coupled Mathematical-Economic Modeling Analysis

    Dec 1, 2024, 00:00

  • EPH2 Costs of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Illness Among Children and Adolescents in Ontario, Canada

    Dec 1, 2024, 00:00

  • HPR121 Characteristics of High-Cost Medicines in the Context of Health Judicialization in Brazil: A Scoping Review

    Dec 1, 2024, 00:00

  • EPH173 A Visual Representation of the Observational Study of Extended Adjuvant Neratinib in HER2+ Early Breast Cancer (EBC) in the Context of the European Early Access Program (EAP): Near Study Final Results

    Dec 1, 2024, 00:00

  • HPR59 Managed Access Protocols As an Innovative Approach to Enabling Access to High-Cost Orphan Medicines: The Irish Experience

    Dec 1, 2024, 00:00

  • EPH204 Health Disparities in Postpartum Complications by Race and Ethnicity: A Marketscan by Merative Retrospective Cohort Analysis

    Dec 1, 2024, 00:00

  • HPR171 Estimating the Impacts of Government-Mandated Price Reductions on Indication Expansion for Launched Drugs: A Real-World Study

    Dec 1, 2024, 00:00

  • EPH16 New Onset Depression During Pregnancy in Commercially-Insured and Medicaid-Insured Pregnancies in the United States

    Dec 1, 2024, 00:00

  • HPR84 The Price Negotiation Phase of the Reimbursement Process in Ireland

    Dec 1, 2024, 00:00

  • HPR197 The Reimbursable Rebate Difference (RRD), an Incentive for Hospitals in France to Negotiate Drug Prices Delivered to Outpatients: What Are the Determinants and Dynamics?

    Dec 1, 2024, 00:00

  • EE745 Health Economic Modelling of Prediabetes Progression and Type 2 Diabetes Risk Based on Published Data From a Swedish Intervention Program

    Dec 1, 2024, 00:00

  • EE270 Cost-Effectiveness Evaluation of Sequential Treatment Stategies for Treatment Naïve Patients With BRAF Mutant Metastatic Melanoma in UK: Nivolumab Plus Ipilimumab First-Line Versus Dabrafenib Plus Trametinib First-Line

    Dec 1, 2024, 00:00

  • HTA90 The NICE Diagnostics Assessment Programme: Does Assessment Lead to Approval?

    Dec 1, 2024, 00:00

  • CO113 Association of Viral Infections in Alzheimer's Disease Among Patients With Mild Cognitive Impairment in Korea

    Dec 1, 2024, 00:00

  • EE443 Cost-Effectiveness Analysis of RSVPreF3 OA Vaccine in Greece for Adults Aged ≥60 Years

    Dec 1, 2024, 00:00

  • HTA79 A Framework for Early Health Technology Assessments of Screening Methods: A Case Study by Evaluating Fracture Risk in Community Dwelling Older Adults

    Dec 1, 2024, 00:00

  • EPH109 Decreased Smoking-Attributable Deaths in Germany With Smoke-Free Products and Tobacco Control Measures: A Modeling Study

    Dec 1, 2024, 00:00

  • EE579 Budget Impact Analysis of Incorporating PlGF in Preeclampsia Screening in Catalonia

    Dec 1, 2024, 00:00

  • EE532 Budget Impact Analyses of Hemoglobin a1C and Lipid Panel Point-of-Care Testing With Afinion™ 2 in Italy and Canada

    Dec 1, 2024, 00:00

  • HSD81 Integrating IPU Principles for Improved Lung Cancer Care at an Oncology Center

    Dec 1, 2024, 00:00

  • EPH186 Assigning Pregnancy Outcomes and Gestational Age at Outcome for Robust Pregnancy Safety Analyses: Application in US Claims

    Dec 1, 2024, 00:00

  • EPH123 Characterization of Trabeculectomy Use and the Impact of COVID-19 in Medicare Beneficiaries With Primary Glaucoma by US Region

    Dec 1, 2024, 00:00

  • HPR170 High-Cost Medicines: Perceptions and Definitions Present in Brazilian Scientific and Academic Production on Health Litigation

    Dec 1, 2024, 00:00

  • EPH105 Prevalence of Metabolic and Micro-Vascular Complications Among English Adult Patients With Type 1 Diabetes Who Were Initiated on Basal Insulin Analogues Between 2014 and 2019: A Population-Based Retrospective Cohort Study

    Dec 1, 2024, 00:00

  • EE811 Cost-Effectiveness Analysis of Spleen Aminopeptide Oral Solution Combined With Conventional Therapy in the Treatment of Adult Patients With Seasonal Allergic Rhinitis in China

    Dec 1, 2024, 00:00

  • EPH11 Burden of HPV-Associated Cancers in Mexico From 2011-2019

    Dec 1, 2024, 00:00

  • HPR240 A Rapid Review of Key Challenges and Success Factors in Implementing Managed Entry Agreements for Pharmaceuticals: Lessons for Greece

    Dec 1, 2024, 00:00

  • HTA150 Analysis of the Change of the Added Benefit and Respective Reasons in Renewed Regular Benefit Assessments of Orphan Drugs Due to Exceeding the Sales Threshold in Germany: Update Until Mai 2024

    Dec 1, 2024, 00:00

  • HTA164 Effective Stakeholder Involvement in Rapid Health Technology Assessments: Five Years of Experience in Argentina

    Dec 1, 2024, 00:00

  • HSD70 Budget Impact of a Minimally Invasive Surgical Treatment for Benign Prostatic Hyperplasia in Australian Public Hospitals

    Dec 1, 2024, 00:00

  • CO39 Efficacy and Quality of Life Benefits of Biologics in Chronic Rhinosinusitis With Nasal Polyposis: A Systematic Literature Review and Meta-Analysis

    Dec 1, 2024, 00:00

  • HTA26 Determining the Value Contribution of Trifluridine/Tipiracil With Bevacizumab for the Treatment of Metastatic Colorectal Cancer in Catalonia Using a Multi-Criteria Decision Analysis

    Dec 1, 2024, 00:00

  • EE549 A Comparative Analysis of Pricing Databases Utilized for Drug Cost Inputs in Health Technology Assessments in Ireland and the UK

    Dec 1, 2024, 00:00

  • EE795 Healthcare Resource Utilization and Costs Associated With Infectious Mononucleosis in the United States

    Dec 1, 2024, 00:00

  • HPR46 Exploring Managed Entry Agreements: A Scoping Review of Approaches, Considerations, and Country-Specific Approaches

    Dec 1, 2024, 00:00

  • EE313 Model-Based Assessment of the Costs and Benefits of Lung Cancer Screening in the Czech Republic Before Introduction of the National Pilot Program

    Dec 1, 2024, 00:00

  • HPR132 Bridging the Gap: Should Health Policy Practices From Western Europe Influence CEE Countries?

    Dec 1, 2024, 00:00

  • EE591 Global Health Economic Burden of Angelman Syndrome: A Systematic Literature Review

    Dec 1, 2024, 00:00

  • EE827 Do Subcutaneous Treatments Provide Most Cost Savings Than Intravenous Treatments in Breast Cancer: A Literature Review

    Dec 1, 2024, 00:00

  • CO29 An Ensemble Approach to Predicting Overall Survival (OS) Benefit Jointly From Multiple Surrogate Endpoints (SE) in Oncology: A Case Study in Previously Untreated Metastatic Melanoma

    Dec 1, 2024, 00:00

  • CO68 Effectiveness and Safety of Avelumab First-Line Maintenance (1LM) in Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): A Systematic Literature Review (SLR) and Meta-Analysis (MA)

    Dec 1, 2024, 00:00

  • EE529 Human Papilloma Virus in Italy: Cost of Illness and Potential Savings Due to HPV9 Primary Prevention in Adult Women

    Dec 1, 2024, 00:00

  • CO55 Estimation of the Effect of Inclisiran in LDL-C Reduction in a Regional Portuguese Population

    Dec 1, 2024, 00:00

  • EE468 A Systematic Review of Health Economic Evaluation on Therapies for the Treatment of Inherited Retinal Diseases: A Quality Evaluation

    Dec 1, 2024, 00:00

  • EPH229 Regional Differences in Morbidity Across Germany: A Cross-State Comparison Using Hospital Data

    Dec 1, 2024, 00:00

  • HSD77 From Centralized Manufacturing to Bedside Production: Advancing CAR T-Cell Therapies Through Collaborative Innovation

    Dec 1, 2024, 00:00

  • HTA105 Has the NICE Methods and Processes Update Accelerated Access to Rare Disease Technologies Routed Via the Single Technology Appraisal (STA) Pathway?

    Dec 1, 2024, 00:00

  • HPR209 Pivotal Studies for Rare Diseases: Will They Better Support Market Access?

    Dec 1, 2024, 00:00

  • HTA58 Methods Used to Adjust for Cross-Over in Clinical Trials: Insights From Scandinavian Health Technology Assessments

    Dec 1, 2024, 00:00

  • EE583 Economic Burden of Dedifferentiated Liposarcoma in Metastatic and Non-Metastatic Patients: A Retrospective Observational Study Using Danish Population-Based Register Data

    Dec 1, 2024, 00:00

  • HTA155 Health Technology Assessment (HTA) of Respiratory Biologics: Highlighting the Differences in Value Assessment of Asthma Interventions Globally

    Dec 1, 2024, 00:00

  • EE384 The Economic Impact of Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Retinopathy (DR), and Diabetic Macular Edema (DME): A Systematic Literature Review of the Emerging Literature

    Dec 1, 2024, 00:00

  • EE731 Ropeginterferon Alfa-2B Is Cost-Effective to Manage Low-Risk Patients With Polycythemia Vera As Compared to Phlebotomy Only

    Dec 1, 2024, 00:00

  • EE486 Budget-Impact Model for the Use of Continuous Monitoring of Patient Vital Signs in US Hospital Medical-Surgical Floors

    Dec 1, 2024, 00:00

  • EPH52 Challenges of Missing Specific Disease Codes: Estimating Incidence and Prevalence of Immunoglobulin A Nephropathy (IgAN) Using Health Insurance Claims Data

    Dec 1, 2024, 00:00

  • EPH209 Incidence of Pulmonary Nodules (PNs) in 2019 in the United States

    Dec 1, 2024, 00:00

  • EE671 Guidance for the Economic Evaluation of Prognostic and Predictive Companion Diagnostics: A Systematic Scoping Review

    Dec 1, 2024, 00:00

  • EE299 Economic Burden of Cardiovascular Diseases in Indonesia: Analysis of BPJS Kesehatan National Health Insurance Claims Data 2021-2022

    Dec 1, 2024, 00:00

  • HSD13 Patient Characteristic, Treatment Pattern, and Healthcare Resource Utilization of Obstructive Hypertrophic Cardiomyopathy (HCM) in China on a Cardiologist Survey

    Dec 1, 2024, 00:00

  • HPR167 Stakeholders' Perspectives on the Use of Patient Registry Data for Decision-Making on Medicines: A Cross-Sectional Survey

    Dec 1, 2024, 00:00

  • HPR38 Top Trends Affecting the Vaccines Market and Their Implications on Access Policy and Public Health Decision-Making

    Dec 1, 2024, 00:00

  • EE810 Cost-Utility Analysis of Empagliflozin on Chronic Kidney Disease Progression in Patients With Chronic Kidney Disease in Thailand

    Dec 1, 2024, 00:00

  • EE756 Cost-Utility Analysis of Single-Inhaler Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate for Maintenance Therapy in Patients With Moderate-to-Severe Uncontrolled Asthma in China

    Dec 1, 2024, 00:00

  • HPR131 Needs and Challenges of the Payor and Regulatory Community Towards Integrating Obesity Into a Chronic Care Framework

    Dec 1, 2024, 00:00

  • HSD22 Perceptions of Physicians on the Diagnosis of Rare Diseases in Europe: Results of a Cross-Sectional Survey

    Dec 1, 2024, 00:00

  • EE400 Cost-Effectiveness of Avacopan for the Treatment of Granulomatosis with Polyangiitis or Microscopic Polyangiitis in Adult Patients in Austria

    Dec 1, 2024, 00:00

  • EE295 Advancing Cancer Treatment With Diagnostic Oncologic Biomarkers in Personalized Medicine in Bulgaria

    Dec 1, 2024, 00:00

  • EE673 Cost-Effectiveness Analysis of ARNI Compared to ACEI Among Heart Failure Patients With Reduced Ejection Fraction in Malaysia

    Dec 1, 2024, 00:00

  • EPH271 Dementia Awareness and Risk Factors Assessment: A Cross-Sectional Study of the Irish Population

    Dec 1, 2024, 00:00

  • EE832 The Lifetime Return on Investment of Measles, Mumps, and Rubella Vaccination in Belgium and Poland

    Dec 1, 2024, 00:00

  • HPR3 Flat Pricing Strategies Across the 8 Major Markets

    Dec 1, 2024, 00:00

  • HSD136 Assessing Gaps in the Timely Referral of Patients for a Rare Disease Diagnosis: A Cross-Sectional Survey of Physicians in Europe

    Dec 1, 2024, 00:00

  • CO98 The Impact of Approved Anti-Obesity Medications on the Incidence of Osteoarthritis, Healthcare Resource Use and Costs Among Patients With Obesity: A Retrospective Cohort Study

    Dec 1, 2024, 00:00

  • EPH28 Revolutionizing Systematic Reviews: The Precision of LLMS in Screening Observational Studies

    Dec 1, 2024, 00:00

  • EE593 The Cost-Effectiveness Outcome of Herbal Medicine (Yukgunja-tang) for the Treatment of Functional Dyspepsia Based on Randomized Controlled Trial in South Korea

    Dec 1, 2024, 00:00

  • HSD36 Medical Devices Index 2023: Access and Sourcing in Portuguese Hospitals, Challenges and Opportunities

    Dec 1, 2024, 00:00

  • HTA98 Patient Consensus on PICO Scoping for the Health Technology Assessment (HTA) Regulation: A Case for Delphi Methodology

    Dec 1, 2024, 00:00

  • EE536 The Benefit of Introducing Remimazolam for General Anesthesia in Belgian Clinical Practice

    Dec 1, 2024, 00:00

  • HPR221 Revisiting Healthcare Resource Allocation for Immunotherapeutic Treatments in Cancer

    Dec 1, 2024, 00:00

  • EE394 Optimized Patient Pathway for Aortic Stenosis Patients: The Economic and Clinical Implications

    Dec 1, 2024, 00:00

  • EPH253 Retrospective Study of Treatment Patterns and Patient Characteristics of Patients With Prostate Cancer Treatment in Germany According to Castration Resistance and Metastatic Status

    Dec 1, 2024, 00:00

  • EE602 Is Universal Screening for Hypothyroidism in Pregnant Women a Cost-Effective Strategy in Indonesia and Mexico?

    Dec 1, 2024, 00:00

  • CO116 Naldemedine Without Rescue Laxatives Versus Either Laxatives or Naloxegol in the Treatment of Opioid Induced Constipation Among Adults With Chronic Non-Cancer Pain

    Dec 1, 2024, 00:00

  • EPH269 Changes in the Prevalence of Early Onset Dementia and Mild Cognitive Impairment in 2020-2023 Compared to 2010-2013 in German General Practices

    Dec 1, 2024, 00:00

  • EE501 Cost-Effectiveness Analysis (CEA) of Pertuzumab and Trastuzumab (PH) + Chemotherapy (CT) Versus H + CT in HER2-Positive Early Breast Cancer (EBC): Updated Model Using Data From the 8.4-Year Follow-up of APHINITY

    Dec 1, 2024, 00:00

  • HTA5 A Review and Evaluation of Reimbursement Outcomes for Non-Orphan and Orphan Drugs in Ireland in 2023

    Dec 1, 2024, 00:00

  • P59 Measuring Health Inequality Aversion in Canada: An Equity-Efficiency Trade-Off Experiment

    Dec 1, 2024, 00:00

  • CO63 Clinical Meaningfulness of Improvements in Quality of Life Observed With Garadacimab Treatment in Patients Living With Hereditary Angioedema: Results From the Pivotal Phase 3 (VANGUARD) Study

    Dec 1, 2024, 00:00

  • HPR40 Determinants of the Prices of Orphan Drugs in France

    Dec 1, 2024, 00:00

  • EPH240 Adapted Targeted Literature Review (ATLR) for Landscaping Trends in Pregnancy Post Authorization Safety Studies (PASS)

    Dec 1, 2024, 00:00

  • EE279 Economic Effects of Self-Applied Patch-Based Polysomnography for Diagnostic Assessment of Obstructive Sleep Apnea in the Netherlands

    Dec 1, 2024, 00:00

  • EPH278 Trends in Epidemiology and Mortality of Patients With Lung Cancer in Germany: A Retrospective Study Using German Claims Data

    Dec 1, 2024, 00:00

  • PT22 Evaluating Reimbursement Pathway of Digital Health Technologies (DHT) Across Five European Countries

    Dec 1, 2024, 00:00

  • EE445 Evaluating the Cost-Effectiveness of Metformin in Prediabetes Management: A Markov Model Analysis Combining Clinical and Real-World Data

    Dec 1, 2024, 00:00

  • EPH98 Disease Burden of Respiratory Syncytial Virus in the US and Germany: A Comparative Analysis of Real-World Data Availability and Opportunities

    Dec 1, 2024, 00:00

  • HPR242 Lump-Sum Envelopes: High Predictability for Payers (Healthcare Product Pricing Committee – CEPS) and Minor Contribution for Companies

    Dec 1, 2024, 00:00

  • EE590 Economic Impact of Diabetes-Related Foot Amputations in Germany From the Payer's Perspective: An Extrapolation of German SHI Data

    Dec 1, 2024, 00:00

  • EE821 Effect of Socioeconomic Status on the Direct Costs of Lupus Nephritis in Colombian Patients

    Dec 1, 2024, 00:00

  • HTA117 Sentiment Analysis of Clinical Evaluations in HTA: Evidence From Canada, England, Scotland, Sweden, France, and Germany

    Dec 1, 2024, 00:00

  • EE651 Evaluating the Cost-Effectiveness of Dabrafenib and Trametinib for the Treatment of Pediatric Patients With Low-Grade Glioma Requiring Systemic Treatment in England and Wales

    Dec 1, 2024, 00:00

  • HPR28 Access to Advanced Therapy Medicinal Products (ATMPs) in Low- and Middle-Income Countries LMICs: A Systematic Review

    Dec 1, 2024, 00:00

  • EE436 Investigation of the Economic Burden of Constipation in Patients With Chronic Musculoskeletal Pain

    Dec 1, 2024, 00:00

  • EPH177 A Multimodal Deep Neural Network for Early Prediction and Detection of Alzheimer's Disease Based on MRI Images and Clinical Information

    Dec 1, 2024, 00:00

  • CO46 Cognitive Assessments in Drug Development in Dementia and MCI: Clinical Trial Landscape Review and Recommendations for Future Neurodegenerative Studies

    Dec 1, 2024, 00:00

  • EE701 The Cost-Effectiveness of an AI-Based Population Wide Screening Programme of Primary Open-Angle Glaucoma in the Netherlands

    Dec 1, 2024, 00:00

  • EPH277 Prevalence, Management, and Comorbid Condition Trends for Obesity Within US Self-Insured Employers

    Dec 1, 2024, 00:00

  • EE479 Real-World Evidence of Healthcare Utilization and Costs for Type 1 Diabetes and Severe Hypoglycemia by Age in Germany

    Dec 1, 2024, 00:00

  • HTA50 Characterizing Evidentiary Critiques in HTA Decision-Making for Treatments Indicated for Overweight and Obesity

    Dec 1, 2024, 00:00

  • HTA160 Structured Expert Elicitation in HTA Submissions: A Practical Guide Using the Example of Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma

    Dec 1, 2024, 00:00

  • EE750 Cell-Based Therapies Reduce Costs and Knee Replacement Surgeries and Increase QALYs Among Knee Osteoarthritis Patients in the Netherlands: A Cost-Effectiveness Study

    Dec 1, 2024, 00:00

  • HTA161 Systematic Review With Indirect Comparison of Efficacy and Safety of Dupilumab Versus Omalizumab for Severe Asthma With Allergic Phenotype

    Dec 1, 2024, 00:00

  • HTA179 A Targeted Review of Treatment Beyond Progression in NICE HTA Oncology Submissions

    Dec 1, 2024, 00:00

  • EE561 Healthcare Resource Utilization Among Patients With Transfusion-Dependent Beta-Thalassemia in the Netherlands

    Dec 1, 2024, 00:00

  • EE558 Economic Evaluations of Treatments for Acquired Hemophilia: A Systematic Literature Review

    Dec 1, 2024, 00:00

  • EE677 Consolidating Methods of Cost-Utility Analysis for Newborn Screening of Spinal Muscular Atrophy: A Systematic Review

    Dec 1, 2024, 00:00

  • EE496 Relugolix/Estradiol/Norethisterone Compared to Tranexamic Acid for Symptomatic Uterine Fibroids in Premenopausal Women (20 to 40 YEAR Old): A Cost-Utility Analysis

    Dec 1, 2024, 00:00

  • EE261 Economic Evaluation of Dupilumab Versus Standard of Care for the Treatment of Adult Patients With Moderate-to-Severe Prurigo Nodularis in the United States

    Dec 1, 2024, 00:00

  • HTA194 Overview of NICE Cost-Comparison Technology Appraisals: Key Takeaways Regarding Comparator Selection and Methods Used to Demonstrate Comparable Efficacy

    Dec 1, 2024, 00:00

  • EE446 Health and Budget Impact of Lenacapavir for HIV Pre-Exposure Prophylaxis in South Africa, Western Kenya, and Zimbabwe: A Modeling Analysis

    Dec 1, 2024, 00:00

  • EE663 Budget Impact Analysis of Fracture Risk Assessment (FRAX) Based Treatment Strategy Selection in Patients With Glucocorticoid-Induced Osteoporosis (GIOP)

    Dec 1, 2024, 00:00

  • EE263 Screening for Type 2 Diabetes Mellitus: A Systematic Review of Economic Evaluations

    Dec 1, 2024, 00:00

  • EE382 Cost of Implementing Alectinib as an Adjuvant Treatment for ALK+ Non-Small Cell Lung Cancer in Denmark (C-ALINA)

    Dec 1, 2024, 00:00

  • HTA128 Kaleidoscope (QALY in Scope): A Conceptual Framework for Contextualizing Value via Dynamic Cost-Effectiveness Threshold

    Dec 1, 2024, 00:00

  • EE656 Challenges in Health-Economic Modeling of Phenylketonuria (PKU): A Targeted Review of HTA Evaluations

    Dec 1, 2024, 00:00

  • PT20 Impact of Huge-Seller Repricing on Price Trend for Reimbursable Cancer Drugs in Japan

    Dec 1, 2024, 00:00

  • EE788 Predicting Health Spending by Risk Level and Severity in a Colombian Health Promotion Entity

    Dec 1, 2024, 00:00

  • HTA201 A Quantitative Assessment of the Economic Decision Drivers Outlined in HTA Outcomes Through Stratification and Sentiment Analysis: Evidence From Canada, England, Scotland, and Sweden

    Dec 1, 2024, 00:00

  • P6 Projected Increase of the Clinical, Economic, Societal, and Environmental Burdens of Chronic Kidney Disease in Switzerland: Insights from Impact-CKD

    Dec 1, 2024, 00:00

  • HPR142 Measuring Impact of HTA on Patient Access to New Medicines in NHS England: A Comparison of Public Health Insurance Funding Restrictions and Patient Uptake for New Medicines across England, France, Germany, and the United States

    Dec 1, 2024, 00:00

  • HPR85 Socioeconomic Impact of Reverse Switching Over-the-Counter (OTC) Antifungal and Antiviral Medicines to Prescription Only Medicines (POM)

    Dec 1, 2024, 00:00

  • HPR92 Price Analysis of Systemic Antibacterial Drugs Approved in the US (January 1980 - December 2020)

    Dec 1, 2024, 00:00

  • HPR123 Assessment of Price Reduction Prediction Based on the Lasted Reimbursement Drug Renewal Rules in China

    Dec 1, 2024, 00:00

  • HTA144 Is Pediatric Indication an Implicit Driver of the French HTA Appraisal Outcomes?

    Dec 1, 2024, 00:00

  • EE717 Influence on Antibiotic Prescribing and Cost Effects Through Standardized Implementation of PoC Testing in Adults With Sore Throats in Standard SHI Care

    Dec 1, 2024, 00:00

  • HTA16 When Timelines Collide: How EMA Regulatory Milestones Can Impact the JCA Process, and Implications for Manufacturers and Member States

    Dec 1, 2024, 00:00

  • HSD120 Evaluating Pre-Treatment Patient Pathways in Early Alzheimer's Disease Management: A Claims Data Analysis in Germany

    Dec 1, 2024, 00:00

  • EE249 The Hidden Burden of Migraine: Analysis Using a Fiscal Framework in Colombia

    Dec 1, 2024, 00:00

  • EE525 Exploring the Implementation of Polygenic Risk Scoring in Alzheimer's Disease: An Early Value Model

    Dec 1, 2024, 00:00

  • EE444 Early Health Technology Assessment of Artificial Intelligence in the Intensive Care Unit: Validation of a Generic Health-Economic Model

    Dec 1, 2024, 00:00

  • EE630 Effects and Costs of Country-Level Hepatitis C Virus Elimination in China: A Modelling Study

    Dec 1, 2024, 00:00

  • HSD65 Optimizing Management and Outcomes of Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS) in Spain: BEWAYAPDS Project

    Dec 1, 2024, 00:00

  • HPR185 Performance-Based vs Finance-Based Managed Entry Agreements (MEAs): Global Trends and Challenges

    Dec 1, 2024, 00:00

  • EPH149 COVID-19 Cases and Deaths by Social Vulnerability in Chicago Community Areas

    Dec 1, 2024, 00:00

  • EE311 Evaluating the Cost-Effectiveness of Ruxolitinib for the Treatment of Polycythaemia Vera Patients That Are Resistant/Intolerant to Hydroxycarbamide/Hydroxyurea in England and Wales

    Dec 1, 2024, 00:00

  • HPR50 The Impact of First Generic Entrance on Public Spending and Medicines Cost: A Case Study in Bulgaria

    Dec 1, 2024, 00:00

  • HPR78 Opportunities and Barriers for the Implementation of the Personalized Medicine in Lithuania

    Dec 1, 2024, 00:00

  • EPH216 Prevalence of Obesity and Overweight in the Maghreb Region: Systematic Review and Meta-Analysis

    Dec 1, 2024, 00:00

  • CO75 A Systematic Literature Review on the Efficacy of Pharmacological Interventions in Ataxia

    Dec 1, 2024, 00:00

  • HPR152 A Comparison of the Acceptability of Evidence in the New Joint Clinical Assessment and Nine European Union Countries

    Dec 1, 2024, 00:00

  • HPR126 Health Economics Centers and Support in SUS Management: A Report of Successful Experiences

    Dec 1, 2024, 00:00

  • EE488 The Potential Public Health Impact of New Immunization Strategies for the Prevention of RSV in Children in Panama

    Dec 1, 2024, 00:00

  • EE611 Cost-Effectiveness of Icosapent Ethyl in Patients With Recent Acute Coronary Syndrome in Catalonia

    Dec 1, 2024, 00:00

  • HTA118 Benefit vs Uncertainties: The Potential Impact of Joint Clinical Assessment (JCA) on Market Access and Reimbursement of Novel Drugs

    Dec 1, 2024, 00:00

  • CO36 Placebo Effect for Clinical Remission in Induction and Maintenance Treatment in Crohn's Disease: A Systematic Literature Review and Meta-Analysis

    Dec 1, 2024, 00:00

  • HPR124 Where HTA Meets Physics: Motion and Acceleration in Access to Innovative Medicines

    Dec 1, 2024, 00:00

  • EE259 Pharmacists as Advocators for Influenza Vaccination in Elderly Patients: A Cost-Effectiveness Analysis

    Dec 1, 2024, 00:00

  • EE334 Use of Disease Analogues to Inform Health-Economic Parameters for Economic Evaluations of Rare Diseases: A Case-Study of Multiple System Atrophy

    Dec 1, 2024, 00:00
  • 1
  • 2
  • 3
  • 4
  • 5 (current)
  • 6
  • 7
  • 8
  • 9
  • 10
  • »